Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD3 | P35462 | 14/20 | 0.61 |
| ▸ | DRD2 | P14416 | 13/20 | 0.61 |
| ▸ | HTR2A | P28223 | 8/20 | 0.61 |
| ▸ | HTR1A | P08908 | 1/20 | 0.50 |
| ▸ | DRD1 | P21728 | 1/20 | 0.50 |
| ▸ | DRD4 | P21917 | 1/20 | 0.50 |
| ▸ | HTR2C | P28335 | 1/20 | 0.50 |
| ▸ | HTR2B | P41595 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13630270 | 1.00 | DRD3 (0.61) | DRD3DRD2HTR2AHTR1ADRD1 | |
| SCHEMBL4486729 | 0.86 | DRD2 (0.60) | DRD3DRD2HTR2A | |
| SCHEMBL13630184 | 0.86 | DRD2 (0.60) | DRD3DRD2HTR2A | |
| SCHEMBL4481761 | 0.86 | DRD2 (0.59) | DRD3DRD2HTR2AHTR1ADRD1 | |
| SCHEMBL13630110 | 0.86 | DRD2 (0.59) | DRD3DRD2HTR2AHTR1ADRD1 | |
| SCHEMBL4487373 | 0.85 | DRD2 (0.58) | DRD3DRD2HTR2AHTR1ADRD1 | |
| SCHEMBL4488376 | 0.85 | DRD2 (0.59) | DRD3DRD2HTR2AHTR1ADRD1 | |
| SCHEMBL13629995 | 0.85 | DRD2 (0.59) | DRD3DRD2HTR2AHTR1ADRD1 | |
| SCHEMBL13630175 | 0.85 | DRD2 (0.59) | DRD3DRD2HTR2AHTR1ADRD1 | |
| SCHEMBL13630453 | 0.85 | DRD2 (0.58) | DRD3DRD2HTR2AHTR1ADRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2038268-B1 | CARBONYLATED (AZA)CYCLOHEXANES AS DOPAMINE D3 RECEPTOR LIGANDS | BIOPROJET SOC CIV (FR) | 2015-11-04 | — | — | EP | claimed |
| US-8802678-B2 | Carbonylated (aza) cyclohexanes as dopamine D3 receptor ligands | BIOPROJET (FR) | 2014-08-12 | — | — | US | claimed |
| US-20090286801-A1 | CARBONYLATED (AZA) CYCLOHEXANES AS DOPAMINE D3 RECEPTOR LIGANDS | BIOPROJET (FR) | 2009-11-19 | — | — | US | claimed |
| CN-101511805-A | As dopamine D3Novel carbonylated (aza) cyclohexanes with receptor ligands | BIOPROJET SOC CIV (FR) | 2009-08-19 | — | — | CN | claimed |
| EP-2038268-B1 | CARBONYLATED (AZA)CYCLOHEXANES AS DOPAMINE D3 RECEPTOR LIGANDS | BIOPROJET SOC CIV (FR) | 2015-11-04 | — | — | EP | disclosed |
| US-8802678-B2 | Carbonylated (aza) cyclohexanes as dopamine D3 receptor ligands | BIOPROJET (FR) | 2014-08-12 | — | — | US | disclosed |
| US-20090286801-A1 | CARBONYLATED (AZA) CYCLOHEXANES AS DOPAMINE D3 RECEPTOR LIGANDS | BIOPROJET (FR) | 2009-11-19 | — | — | US | disclosed |
| CN-101511805-A | As dopamine D3Novel carbonylated (aza) cyclohexanes with receptor ligands | BIOPROJET SOC CIV (FR) | 2009-08-19 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090286801-A1 | CARBONYLATED (AZA) CYCLOHEXANES AS DOPAMINE D3 RECEPTOR LIGANDS | DRD3, TACR2, TACR1 | DRD3 1/4885DRD2 4/4885HTR2A 225/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.